Dhaka, March 2 -- The "Ertu Ramadan Study Dissemination Program" concluded recently with a significant milestone in diabetes research at Pan Pacific Sonargaon, Dhaka.

Organised by Synovia Pharma PLC, the event celebrated the publication of the Ertu Ramadan Study in Frontiers in Endocrinology (Impact Factor: 3.9), shedding light on the real-world effectiveness of Ertugliflozin in managing Type-2 diabetes mellitus (T2DM) during Ramadan fasting, according to a press release.

The chief guest at the event was Dr AK Azad Khan, President of the Diabetic Association of Bangladesh (BADAS). M A Samad, CEO of the National Health Network (NHN), was present as a special guest.

Professor Dr Hafizur Rahman, Department of Endocrinology, United Hospita...